International law firm Simmons & Simmons has advised on the AIM placing and subscription completed on 17 April 2018 by NetScientific plc, the transatlantic healthcare IP commercialisation group.

The team advised the nominated adviser and broker Stifel Nicolaus Europe Limited and placing agent Liberum on the placing and subscription of 9,523,809 new ordinary shares at 52.5 pence per share, raising a total of £5m for NetScientific (before expenses).

This follows the team’s previous work for Stifel Nicolaus Europe Limited and placing agent Liberum on NetScientific’s AIM placing and subscription in May 2017, which raised £8m.

Additionally, in the last year the UK team has advised Stifel Nicolaus Europe Limited and joint broker WG Partners on the dual listing of Novacyt, an international diagnostics company, and the shareholders of Intelligent Ultrasound Limited (IUL) on the disposal of the company to MedaPhor Group plc, Their specific AIM experience with life sciences companies includes acting for REX Bionics plc and Venture Life plc on their flotations and further deals as public companies, as well as JP Morgan on the record-breaking £581m Circassia IPO, Cenkos Securities on the £20m AIM IPO of Creo Medical Group, and Stifel on the £20m AIM IPO of Oxford BioDynamics.

This is the latest in a series of transactions that the firm has advised on in the healthcare & life sciences sector. The firm is recognised worldwide advising pharma, biotech, medical device, digital and other healthcare companies, with a growing number of deals in the digital health space, such as our Singapore team’s recent work with NSI Ventures and Aviva Ventures on their investment in health-tech start-up Biofourmis.

Commenting on the transaction, partner Charles Mayo, said: " We take great pride in helping listed healthcare & life sciences companies to raise capital successfully."

The Simmons & Simmons team was led by Charles Mayo, assisted by Tim Wass and Haya Aftab.